Abpro Holdings, Inc.

Abpro Holdings, Inc. is a biotechnology company that develops advanced antibody treatments for patients with severe and life-threatening diseases. The company focuses on creating new antibodies using its specialized discovery and engineering platforms. Its primary areas of focus are immuno-oncology, ophthalmology, and infectious disease. On November 13, 2024, Atlantic Coastal Acquisition Corp. II (ACAB) completed a merger with Abpro Corporation (Legacy Abpro). Following the merger, ACAB changed its name to Abpro Holdings, Inc., and Legacy Abpro became a wholly owned subsidiary of the company. Shares of Abpro Holdings, Inc. common stock began trading on the Nasdaq Global Market on November 14, 2024. However, due to multiple Nasdaq continued listing non-compliance issues, the company received a delisting notice effective February 23, 2026. Its securities currently trade on the OTC Pink Limited Market under the ticker symbol ABPO for common shares. The company appealed the Nasdaq delisting determination on March 18, 2026. For financial reporting purposes, the merger was treated as a reverse recapitalization, with ACAB considered the acquired company and Legacy Abpro the acquirer. The company's operations prior to the merger are those of Legacy Abpro.